Profil
Diane Tang-Liu is the founder of AiViva BioPharma, Inc., which she founded in 2015 and where she currently holds the titles of President, Chief Executive Officer & Director.
She is also currently the President, Chief Executive Officer & Director of AiViva Holding Ltd.
Postes actifs de Diane Tang-Liu
| Sociétés | Poste | Début |
|---|---|---|
AiViva Holding Ltd.
 AiViva Holding Ltd. Financial ConglomeratesFinance AiViva Holding Ltd. functions as an investment holding company. The company is based in Newport Beach, CA. The CEO of the company is Diane Tang-Liu. | Directeur Général | - |
Aiviva Biopharma, Inc.
 Aiviva Biopharma, Inc. Pharmaceuticals: MajorHealth Technology AiViva BioPharma, Inc. is a clinical stage biotech company based in Costa Mesa, CA. AiViva is developing new therapeutics using innovative approaches, with proprietary technologies, including Jel™, to address high unmet medical needs through focal therapies that target diseases of neovascularization, abnormal cell proliferation, and fibrosis. The private company's core competencies include the development of novel drugs in specialty therapeutic areas of dermatology, ophthalmology, urology, and oncology. An estimated 100 million people in the developed world form scars following surgery. The company was founded in 2015 by Diane Tang-Liu, who has been the CEO since then. | Fondateur | 01/01/2015 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
AiViva Holding Ltd.
AiViva Holding Ltd. Financial ConglomeratesFinance AiViva Holding Ltd. functions as an investment holding company. The company is based in Newport Beach, CA. The CEO of the company is Diane Tang-Liu. | Finance |
Aiviva Biopharma, Inc.
Aiviva Biopharma, Inc. Pharmaceuticals: MajorHealth Technology AiViva BioPharma, Inc. is a clinical stage biotech company based in Costa Mesa, CA. AiViva is developing new therapeutics using innovative approaches, with proprietary technologies, including Jel™, to address high unmet medical needs through focal therapies that target diseases of neovascularization, abnormal cell proliferation, and fibrosis. The private company's core competencies include the development of novel drugs in specialty therapeutic areas of dermatology, ophthalmology, urology, and oncology. An estimated 100 million people in the developed world form scars following surgery. The company was founded in 2015 by Diane Tang-Liu, who has been the CEO since then. | Health Technology |
